Cite
HARVARD Citation
Antoniotti, C. et al. (2022). Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet oncology. 23 (7), pp. 876-887. [Online].